Name of the Procedure:

Common name: Plasma, Cryoprecipitate Reduced
Technical term: P9044

Summary

Plasma, cryoprecipitate reduced, is a blood product that has had its cryoprecipitate (a component rich in clotting factors) removed. This procedure involves the administration of this specially processed plasma to patients who need it for various medical reasons.

Purpose

This plasma product is used to manage and treat conditions related to blood clotting disorders. The goal is to provide necessary plasma proteins while minimizing the risk of hypercoagulability that might be caused by the cryoprecipitate component in certain patients.

Indications

• Patients with thrombotic tendencies needing plasma but without the additional clotting factors present in cryoprecipitate.
• Management of patients with thrombotic thrombocytopenic purpura (TTP).
• Situations where fresh frozen plasma is indicated but an excess of clotting factors is not desirable.

Preparation

• Typically, no fasting required.
• Patients may need to stop certain medications as directed by their healthcare provider.
• Prior blood tests to determine specific needs and compatibility.

Procedure Description

1. Blood Collection: Blood is drawn from a donor.
2. Separation: Plasma is separated from the red cells and white cells.
3. Cryoprecipitate Removal: The plasma is processed to remove the cryoprecipitate component.
4. Transfusion: The processed plasma is transfused into the patient through an intravenous line.

Tools and Equipment:

• Blood separation equipment.
• Sterile intravenous catheters and transfusion sets.
• Blood plasma processing facilities.

Anesthesia/Sedation: Typically not required.

Duration

The actual transfusion process typically takes between 30 minutes to an hour per unit, depending on the patient's condition and response.

Setting

This procedure is done in a hospital setting, often in a specialized infusion or transfusion unit.

Personnel

• Physicians specializing in hematology or transfusion medicine.
• Registered nurses trained in transfusion procedures.
• Medical technicians handling blood processing.

Risks and Complications

Common risks:

• Allergic reactions.
• Fever and chills.

Rare risks:

• Transfusion-related acute lung injury (TRALI).
• Infections or transfusion-transmitted diseases.
• Volume overload, particularly in patients with heart conditions.

Benefits

• Management of clotting disorders.
• Reduced risk of hypercoagulability.
• Symptomatic relief and stabilization of the patient’s condition.

Benefits are often realized shortly after the transfusion, as clotting factors are normalized.

Recovery

• Post-transfusion monitoring for any immediate reactions.
• Instructions on what symptoms to watch for and when to seek medical help.
• Most patients can resume normal activities shortly after recovery, barring any complications.

Alternatives

• Fresh frozen plasma (FFP).
• Specific factor concentrates for particular clotting disorders.
• Each alternative has pros and cons depending on the patient's specific condition and the desired outcomes.

Patient Experience

During the procedure, patients might feel the initial needle prick and some discomfort as the IV is set up. Most patients report minimal discomfort during the transfusion. Post-procedure, patients may need to stay for observation to ensure there are no adverse reactions. Pain management is typically not needed but will be provided if necessary.